You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B

    SBC: NECTAGEN INC            Topic: NIAID

    Infection with the bacterium C. difficile is the most common and increasingly prevalent cause of diarrhea. In the United States, cases of C. difficile infection (CDI) are estimated to number 500,000 annually and to result in an estimated 15,000 to 30,000 deaths. The cost of these cases is thought to exceed $4.8 billion annually. CDI continues to cause discomfort, serious illness and sometimes deat ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. 3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring

    SBC: Axioforce LLC            Topic: NIBIB

    PROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a clinical diagnostic tool for age-related cochlear synaptopathy.

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIA

    Age-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma

    SBC: Sarya, LLC            Topic: 102

    PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. STARTUP Central

    SBC: CONTINUUM EDUCATIONAL TECHNOLOGIES, PBC            Topic: 500

    PROJECT SUMMARY Continuum Educational Technologies’ (Continuum) will work with the University of Kansas (KU) on the proposed I-RED program entitled Smart Tools to Accelerate Research Translation by Uplifting Participants for the Central IDeA State Region (STARTUP Central) program to stimulate technological innovation in the IDeA state regions by addressing the entrepreneurial educational needs o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Electrochemical Biosensor Based Rapid Diagnostic Platform for Quantitative Detection Controlled Substance Related Metabolites

    SBC: FOOTHOLD LABS INC            Topic: AFX20DTCSO1

    Electrochemistry-based sensors have been shown to provide reliable, rugged, low-cost solutions for analyte detection. Common uses for electrochemical sensors are smoke and carbon monoxide detectors, industrial gas sensors, and insulin monitors. However, e

    STTR Phase II 2023 Department of DefenseAir Force
  8. Dynamhex with UMKC uses AI to help organizations quantify, manage and scale climate impact

    SBC: DYNAMHEX, INC.            Topic: AF21BTCSO1

    Dynamhex helps customers manage climate change targets and energy transition plans with data-backed, actionable and cost-effective solutions. Dynamhex uses AI models to process timely, standardized and localized data down to the component level and presen

    STTR Phase I 2022 Department of DefenseAir Force
  9. Keeping Cool without Fossil Fuel- concentrated solar powered air-conditioning for reduced power consumption in austere operating conditions and at fixed USAF bases

    SBC: HyperBorean, LLC            Topic: AF21BTCSO1

    HyperBorean has developed air cooling solutions which operate off-grid and are powered by sources of no-cost heat in lieu of electricity. Sources of heat input for HyperBorean’s systems include concentrated solar and the waste heat generated by internal c

    STTR Phase I 2022 Department of DefenseAir Force
  10. Mitofusin Agonists to Treat Neurodegenerative Disease

    SBC: Mitochondria in Motion, Inc.            Topic: 104

    Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: A number of rare neurodegenerative diseases are characterized by mitochondrial fragmentation, dysmotility and dysfunction. Among these are Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), which cause ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government